Home / Central Data Catalog / PAR / NMIMR_LYPHATIC_FILARIASIS_2007
Par

Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial

Ghana
Get Microdata
Reference ID
NMIMR_LYPHATIC_FILARIASIS_2007
DOI
https://doi.org/DOI 10.1186/s13063-017-2196-9
Producer(s)
Dziedzom K. de Souza
Collections
Parasitology
Metadata
Documentation in PDF DDI/XML JSON
Created on
Jun 07, 2023
Last modified
Jul 14, 2023
Page views
603

Identification

Survey ID Number
NMIMR_LYPHATIC_FILARIASIS_2007
Title
Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial
Country
Name Country code
Ghana GH
Kind of Data
sample survey data[ssd]

Version

Version Description
v1

Scope

Notes
Abstract
Background: The Global Programme for the Elimination of Lymphatic Filariasis (GPELF) has been in operation since
the year 2000, with the aim of eliminating the disease by the year 2020, following five to six rounds of effective
annual mass drug administration (MDA). The treatment regimen is ivermectin (IVM) in combination with
diethylcarbamazine (DEC) or albendazole (ALB). In Ghana, MDA has been undertaken since 2001. While the disease
has been eliminated in many areas, transmission has persisted in some implementation units that had experienced
15 or more rounds of MDA. Thus, new intervention strategies could eliminate residual infection in areas of
persistent transmission and speed up the lymphatic filariasis (LF)-elimination process. This study, therefore, seeks
to test the hypothesis that biannual treatment of LF-endemic communities will accelerate the interruption of LF in
areas of persistent transmission.
Methods: A cluster randomised trial will be implemented in LF-endemic communities in Ghana. The interventions
will be yearly or twice-yearly MDA delivered to entire endemic communities. Allocation to study group will be by
clusters identified using the prevalence of LF. Clusters will be randomised to one of two groups: receiving either (1)
annual treatment with IVM+ ALB or (2) annual MDA with IVM+ ALB, followed by an additional MDA 6 months later.
The primary outcome measure is the prevalence of LF infection, assessed by four cross-sectional surveys.
Entomological assessments will also be undertaken to evaluate the transmission intensity of the disease in the study
clusters. Costs and cost-effectiveness will be evaluated. Among a random subsample of participants, microfilaria
prevalence will be assessed longitudinally. A nested process evaluation, using semi-structured interviews, focus group
discussions and a stakeholder analysis, will investigate the community acceptability, feasibility and scale-up of each
delivery system.

Producers and sponsors

Primary investigators
Name Affiliation
Dziedzom K. de Souza epartment of Parasitology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon-Accra, Ghana

Data Collection

Data Collection Mode
Household-level questionnaire

Access policy

Contacts
Name Affiliation Email
Dziedzom K. de Souza Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana balogonia@noguchi.ug.edu.gh
Access authority
Name Affiliation URL Email
Dziedzom K. de Souza Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana www.noguchi.ug.edu.gh DdeSouza@noguchi.ug.edu.gh
Copyright
Noguchi Memorial Institute for Medical Research
Back to Catalog